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Abstract
Purpose: To evaluate whether immunomodulation can eliminate high sustained antibody levels, and thereby
improve clinical outcome in classic infantile Pompe patients receiving enzyme replacement therapy (ERT) with
recombinant human alpha-glucosidase (rhGAA).
Methods: Three patients (two cross-reactive immunologic material (CRIM) negative) with high sustained antibodies
received a three-week treatment protocol with Rituximab and Bortezomib, followed by daily Rapamycin and
monthly IVIG. Patients received 40 mg/kg/week rhGAA. Antibody titers were measured using ELISA. Neutralizing
effects on cellular uptake were determined. Clinical efficacy was measured in terms of (ventilator-free) survival,
reduction in left ventricular mass index (LVMI) and improvement in motor function.
Results: Before immunomodulation anti-rhGAA antibody titers ranged from 1:156,250 to 1:781,250 and at last
assessment from 1:31,250 to 1:156,250. Neutralizing effects of anti-rhGAA antibody titers (observed in two patients)
disappeared. Infusion-associated reactions were no longer present. Immunomodulation resulted in substantial
increases of aspartate transaminase, alanine transaminase, and creatine kinase levels. The two CRIM-negative
patients who could walk at start of immunomodulation maintained their ability to walk; the patient who had lost
this ability did not regain it.
Conclusions: To some extent, the immunomodulation protocol used in our study reduced antibody titers, but it
did not eliminate them. Overall, there have been few reports on secondary immunomodulation, and various protocols
have been applied. Future research should seek to identify the most successful immunomodulation protocol in patients
with high sustained titers.
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Background
Pompe disease (Glycogen Storage Disease type II,
OMIM #232300), an autosomal recessive lysosomal stor-
age disorder caused by deficiency of acid-α-glucosidase
(GAA), results in lysosomal glycogen accumulation in all
cell types, but mainly in muscle cells [1]. Pompe disease
presents as a spectrum of clinical phenotypes, the classic
infantile form being the most severe form [2]. Classic in-
fantile patients have less than 1% of enzyme activity in
fibroblasts and present with hypertrophic cardiomyop-
athy (HCM), progressive generalized muscle weakness,
and respiratory difficulties. Without treatment, patients
die within the first year of life due to cardiorespiratory
failure [3–5].
Enzyme replacement therapy (ERT) with recombin-
ant human alpha-glucosidase (rhGAA, alglucosidase
alfa, Myozyme) has improved prognosis for patients
by improving survival and improving motor outcome.
[6, 7]. Clinical response varies greatly between patients
[6, 8–11]. A higher dose of ERT has been shown to posi-
tively influence patients’ outcome [6, 12, 13]. Antibodies
to rhGAA may counteract positive effects of ERT by
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neutralizing its activity or preventing cellular uptake
[12, 14–16]. Cross-reactive immunologic material
(CRIM negative) patients (who produce no GAA pro-
tein) are more likely to form higher anti-rhGAA anti-
bodies titers than CRIM-positive infantile patients
(who produce inactive GAA protein). Generally,
CRIM-negative patients have been reported to re-
spond poorly to ERT [14, 16–18]. Despite reports that
antibody formation can be prevented successfully by
primary immunomodulation (i.e., using a combination
of Rituximab (RTX), Methotrexate (MTX) and intra-
venous immunoglobulin (IVIG) before the first ERT
dose) [8, 19–21], some patients still develop high
anti-rhGAA antibody titers [21–23].
There have also been attempts at secondary immuno-
modulation, i.e., eliminating anti-rhGAA antibodies in
patients who have developed high titers during ERT.
The best reported results involved a protocol using
Bortezomib, a proteasome inhibitor that induces apop-
tosis in plasma cells by dysregulating signaling cascades
[24]. So far, the data that has been published is on very
few patients, whose outcome also vary [19, 20, 25–28].
We studied the effects of secondary immunomodulation
on anti-rhGAA antibody titer formation, the cellular up-
take of GAA, the depletion and repopulation of B cells,
and clinical outcome using a protocol combining Rituxi-
mab, Bortezomib, Rapamycin and IVIG.
Methods
Patients and treatment protocol
We included three patients with classic infantile Pompe
disease who had high sustained anti-rhGAA antibodies
(≥1:31.500) and whose quality of movement and/or
motor performance raised concerns. Two patients did
not receive immunomodulation previously, while
(patient 2 did [23]). Classic infantile Pompe disease was
defined as symptoms of muscle weakness within 6
months after birth, the presence of HCM, complete defi-
ciency of α-glucosidase in fibroblasts (< 1% of normal
values), and two very severe mutations in the GAA gene.
Patients were already participating in an ongoing study
into the effects of ERT, study protocols had been
approved by the Institutional Review Board. Written
informed consent was obtained from the parents. ERT
was dosed at 40 mg/kg/week.
Immunomodulation protocol
Our immunomodulation protocol for patients with
high titers was derived from protocols published by
Messinger et al., Banugaria et al. and Elder et al.
[19, 22, 24]. The following immunomodulation regimen
was applied: 3 weekly infusions of RTX 375mg/m2; 6
twice-weekly doses of Bortezomib 1.3mg/m2; monthly
IVIG (first dose 1.0 g/kg; subsequent doses of 0.5 g/kg);
Rapamycin was commenced at week 4 (10–20 kg 1.0–1.5
mg/day; 20–30 kg 1.5–2.0mg/day; double dose on first
day of Rapamycin treatment). Dose was adjusted on the
basis of serum Rapamycin levels (normal range 4–12 μg/l).
To reduce the risk of infections, all patients received
Azithromycin prophylactically. Regular blood analysis
consisted of determining the number of B cells and the
levels of aspartate transaminase (AST), alanine transamin-
ase (ALT), creatine kinase (CK), and gamma globulin
(IgG, IgM, IgA).
Antibody titer and neutralizing effects
Blood samples were drawn at regular intervals and
stored at − 80 °C until analysis. Anti-rhGAA antibody ti-
ters were determined by enzyme-linked immunosorbent
assay (ELISA) as described earlier [16, 17]. Experiments
were performed in duplicate and assays were repeated at
least twice. Our figures present the highest titers mea-
sured. The neutralizing effects of antibodies were deter-
mined at least twice per patient by studying their effect
on cellular uptake in vitro. Fibroblasts from a patient
homozygous for the 525delT mutation fully deficient in
acid α-glucosidase production were seeded in 24-well
tissue-culture plates and maintained at 37 °C in Ham’s
F10 medium supplemented with 10% FCS and antibi-
otics. To measure the uptake of alglucosidase alfa, we
added Pipes to the medium in a final concentration of 3
mM to make the medium slightly acidic (pH 6.8). The
enzyme was added in an amount equivalent to 200 nmol
MUGlc/h per 200 μL medium. Finally, 20 μL of the pa-
tients’ sera were added. Uptake of alglucosidase alfa was
measured in cell homogenates. MUGlc was used as sub-
strate”. As control the same experiment was performed
without addition of 20 μL of the patients’ sera. GAA
activity was expressed as percentage of control. The
experiment was performed in duplicate [16, 17].
Clinical outcome measures
Standardized assessments were performed at start of
ERT and every three months thereafter [6], and also at
start of immunomodulation. Clinical outcome parameters
were (ventilator-free) survival, left ventricular mass index
(LVMI, where an LVMI Z-score ≥ +2SD was defined as ab-
normal); pulmonary function tests; and motor function
assessed by Alberta Infant Motor Scale (AIMS); Bayley
Scales of Infant Development II (BSID-II); 10-m run test,
and 6-min walk test (6MWT). Infusion-associated
reactions (IARs) were recorded [29–34].
Case reports
Patient 1
Patient 1 (CRIM-positive) started ERT at 2.4 months
(Table 1). At birth she had presented with persistent
tachypnea and HCM attributed initially to gestational
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diabetes in her mother. At the time of diagnosis she
had severe hypotonia and a prominent head lag.
When prone she could not lift her head from the sur-
face, and anti-gravity movements of the limbs were
not observed (AIMS score was 1). She was still able
to drink (weight 6.5 kg + 2.0 SD for Dutch children)
and did not require nasogastric tube (NGT) feeding.
During ERT, LVMI normalized, with the LVMI
z-score decreasing from 22.5 to 1.75 during the first
9 months of ERT (Fig. 3e). She learned to walk
unsupported at the age of 15 months. At the age of
2.5 years she developed a transient right-sided facial
nerve palsy elicited by a herpes simplex viral infec-
tion. From then on she experienced frequent airway
and urinary tract infections, accompanied by transient
periods of poorer motor functioning. She maintained
the ability to walk until the age of 6 years. From the
age of 6.1 years, motor function started to decline. At
Table 1 Patient Characteristics
Patient 1 Patient 2a Patient 3
Baseline and initial response
Age at start (in months) 2.4 5.8 1.9
Mutations c.2481 + 102_2646 + 31del538 c.del525T c.del525T
c.2481 + 102_2646 + 31del538 c.del525T c.del525T
CRIM status Positive Negative Negative
Ventilatory support No No No
LVMI at start in g/m2 (z-score) 237 (22.5) 265 (26.1) 200 (17.8)
Time to LVMI normalization (z-score) 9 months (1.75) 6 months (1.43) 9 months (0.1)
Age pull to stand (in months) 11.6 14.8 9.2
Age walking (in months) 15 21.3 11.7
NGT at start No Yes Yes
Age at which NGT ended (in months) N.A 21 9
Total number of IARs (total severe IARs) 70 (6) 22 (5) 16 (0)
Age at last IAR (in years) 4.0 3.5 2.1
At start of secondary immunomodulation
Age in years 6.6 3.5 2.3
Ventilatory support No No No
LVMI in g/m2 (z-score) 70.6 (0.4) 63.2 (0.5) 83.9 (3.1)
Best motor function Sitting Walking Walking
Antibody titer 1:156,250 1:156,250 1:781,250
Enzyme activity in cell lysates 50% 60% 100%
At study end
Age in years 9.1 5.6 3.8
Ventilatory support No No No
LVMI in g/m2 (z-score) 82.5 (1.3) 65 (0.7) 55 (−0.5)
Best motor function Sitting Walking Walking
NGT/PEG (age in years) Yes (7.0) No No
Last antibody titer (time since last RTX in years) 1:31,250 (0.5) 1:31,250 (2) 1:1561,250 (1.5)
Enzyme activity in cell lysates 100% 100% 100%
B-cell normalization/time since last RTX in months Yes/14
No/5c
Yes/6 Yes/3
Last B-cell levelb 0 0.85*109/L 0.48*109/L
IARs since start of immunomodulation No No No
CRIM cross-reactive immunologic material, LVMI left ventricular mass index, NGT nasogastric tube, IAR infusion-associated reaction, PEG percutaneous endoscopic
gastrostomy tube, RTX Rituximab
aPatient 2 initially received immunomodulation in an ERT naïve setting.
bB- cell normal range; for age 2–5 years normal range of 0.2–2.1*10E9, for age 5–10 years normal range of 0.2–1.6*10E9
cAfter an initial round of immunomodulation patient 2 received a second round of immunomodulation 2 years later because of high rhGAA antibodies
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the age of 6.4 years she was no longer able to stand
unsupported.
Patient 2
Patient 2 (CRIM-negative) started ERT at 5.8 months
(Table 1). At 5 months he was hospitalized due to feed-
ing difficulties and muscle weakness accompanied by
HCM. At time of diagnosis he was able to lift his limbs
from the surface, but could not roll over. Due to insuffi-
cient oral intake, NGT feeding was started. Primary
immunomodulation was started before the first ERT
dose [23]. During ERT, LVMI normalized, with the
LVMI z-score decreasing from 26.1 to 1.4 during the
first 6 months of ERT (Fig. 3e). NGT feeding could be
stopped at age of 21 months. He learned to walk unsup-
ported at 21 months. After a fall he lost the ability to
walk for 4 months (age 2.5 years), but then regained it
without intervention. Due to the concerns raised by his
quality of movement and the reoccurrence of IARs, a
second round of immunomodulation was initiated.
Patient 3
Patient 3 (CRIM-negative) started ERT at 1.9 months
(Table 1). There were feeding difficulties from birth on-
wards. Shortly after a chest X-ray at the age of 5 weeks
had revealed HCM, she was diagnosed with Pompe dis-
ease. At time of diagnosis she could lift her limbs from
the surface, could turn her head when in prone position,
and could take some support on her legs. Due to insuffi-
cient intake, an NGT was placed. After start of ERT,
LVMI normalized, with LVMI z-score decreasing from
17.8 (LVMI 200 g/m2) to 0.1 during the first 9 months of
ERT (Fig. 3). NGT feeding could be stopped at the age
of 9 months. She learned to walk unsupported at the age
of 11 months, and obtained the maximum AIMS score
of 58 at the age of 12 months (Fig. 3). After her first
birthday, she gradually started to perform more poorly
than age-related peers (BSID II scores, Fig. 3e). She also
developed a Gower’s sign and her calves became hyper-
trophic. LVMI increased slightly (LVMI 80.7 g/m2,
z-score 2.7) without functional consequences.
Results
Effects of immunomodulation on B cells
After RTX treatment B cells became depleted in all
patients (Table 1). In patients 1, 2 and 3 time to B-cell
recovery was 1.2 years, 6 and 3months, respectively.
During B-cell depletion all patients received IVIG.
Patient 1 who received the first round at the age of 6.6
years received a second round of immunomodulation at
8.5 years. At study end there was no B-cell recovery.
Anti-rhGAA antibody titers before and after
immunomodulation
Anti-rhGAA antibody titers are shown in Figs. 1 (from
start of ERT) and 2 (after immunomodulation). In
patient 1, anti-rhGAA antibodies were first detected at
one month of ERT (titer 1:250, Fig. 1). This increased to
Fig. 1 Anti-rhGAA antibody titers. Anti-rhGAA antibody titers per
patient during follow-up. Panel a is patient 1. Panel b is patient 2.
Panel c is patient 3. Anti-rhGAA antibody titers before
immunomodulation are shown as closed symbols. The open
symbols represent titers after immunomodulation
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a maximum titer of 1:31,250, which was maintained be-
tween the ages of 0.4 and 6.2 years. At start of secondary
immunomodulation at 6.4 years, her titer was 1:156,250.
In patient 2, who had started primary immunomodula-
tion before start of ERT, anti-rhGAA antibodies were
first detected at 5.5 months of ERT (titer 1:1250). These
increased to the highest maximum titer of 1:800,000 be-
tween the ages of 1.6 and 2.7 years [23]. This patient had
received MTX in a dose of 0.5 mg/kg/week until 5 days
before start of secondary immunomodulation. At start of
secondary immunomodulation at 3.5 years, his titer was
1:156,250. In patient 3, anti-rhGAA antibodies were first
detected at one month of ERT (1: 31,250). These in-
creased to a titer of 1:781,250, which was maintained
until start of secondary immunomodulation at the age of
2.3 years.
The immunomodulation schedule per patient is shown
in Fig. 2, as well as the effects on anti-rhGAA antibody
titer. In patient 1 anti-rhGAA antibody titers decreased
from 1:156,250 to 1:31,250 one month after start of
immunomodulation, but rose again to 1:156,250 a
month later. The high sustained titers were the reason
for starting a second round of immunomodulation 2
years later. Titers decreased to 1:31,250. In patient 2,
anti-rhGAA antibody titers decreased from 1:156,250 to
1:6250; his last titer was 1:31,250. In patient 3,
anti-rhGAA antibody titers decreased from 1:781,250 to
1:156,250.
Neutralizing effects of antibodies
To test for neutralizing effects of anti-rhGAA antibodies,
GAA-deficient fibroblasts were incubated with alglucosi-
dase alpha plus patients’ serum. Enzyme activity was
measured in medium and fibroblast cell lysates (Fig. 2).
In patient 1, no neutralizing effects of anti-rhGAA anti-
bodies had been observed at the ages of 0.4 and 3.2 years
(activity in cell lysates 100 and 83% compared to the ac-
tivity in controls [16]). At age 6.4 years enzyme activity
in cell lysates was 49.7%. In patient 2, enzyme activity in
cell lysate decreased from 79.8% at the age of 2.1 years
to 60% at the age of 2.7 years [23]. In patient 3 enzyme
activity in cell lysate was 93.7% at age of 2.1 years.
Figure 2 shows the effects of immunomodulation on
neutralizing effects. At the ages of 7.6 years (patient 1),
3.6 years (patient 2), and 2.5 years (patient 3), no neutral-
izing effects of anti-rhGAA antibodies were observed
respective enzyme activity in cell lysates of 145, 165,
147%).
Clinical outcome measures
At study end, all patients were alive, none required ven-
tilatory support (Table 1), and LVMI was within normal
Fig. 2 Effects of immunomodulation. Each column represents a single patient. Upper row: Anti-rhGAA antibody titer in detail after immunomodulation,
as shown previously in Fig. 1 (line with symbols on the left axis), and neutralizing effects of anti-rhGAA antibodies (crosses, on the right axis). Middle
row: Serum B-cell levels per patient (black line on the left axis) and Rapamycin serum levels per patient (grey dashed line on the right axis). Dotted
grey line represents the lower level of normal for B cells for age, which is 0.2*10E9/l. Bottom row: Immunomodulation treatment per patient. Verticals
stripes represent each individual IVIG infusion. Horizontal lines represent the period in which Rapamycin taken. Squares represent each cycle of 6
Bortezomib infusions. Circles represent each cycle of 3 Rituximab infusions
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limits (Fig. 3a). Patient 1 had lost the ability to walk
before start of immunomoulation (Fig. 3d) and did not
regain it. Patients 2 and 3 maintained the ability to walk.
Figure 3b-e shows the motor performance of all three
patients (AIMS, BSID II, 6MWT) and time they needed
to run 10m) before (closed symbols) and after start of
secondary immunomodulation (open symbols). At the
end of the study period, when patient 3 was aged 3.8
years, her BSID II scores were within normal limits; be-
fore, they had been slightly lower. It should be noted
that around this age, all three patients—including those
who had not yet started secondary immunomodula-
tion—had had similar age-equivalant scores. Patient 3
was too young to perform the 6MWT. For patient, 2 the
distance walked during the 6MWT remained stable over
a period of 1.5 years. Pulmonary function tests could be
performed only in patient 1 (Fig. 3f ): before immunomo-
dulation, the percentage of predicted of the forced vital
capacity (FVC) had ranged between 59 and 75%; after
immunomodulation it ranged from 46 and 60%.
Safety and effects on IARs
Before start of secondary immunomodulation, all
patients had experienced IARs (Table 1). After the start
of secondary immunomodulation, no IARs were ob-
served. Immunomodulation was well tolerated. None of
the patients experienced serious infectious diseases. Mild
erythema was observed at the Bortezomib injection site
in all patients. No other adverse events were reported.
At last observation, all patients were still receiving daily
Rapamycin and monthly IVIG. Over the course of two
to three months after the start of secondary immunomo-
dulation, AST, ALT and CK levels all increased in the
three patients, the increase in CK levels being the most
prominent (from 842 to 3175 U/l (patient 1); from 1537
to 2939 U/l (patient 2); and from 3451 to 5363 U/l
(patient 3), Additional file 1). The increase in CK levels
remained unexplained.
Discussion
In this study, we evaluated the effect of a secondary
immunomodulation protocol using Rituximab, Bortezo-
mib, Rapamycin and IVIG, to improve or stabilize clin-
ical outcome of three classic infantile patients with high
sustained antibody titers. We observed B-cell depletion
and recovery in all three patients. Before immunomodu-
lation anti-rhGAA antibody titers ranged from 1:156,250
to 1:781,250. At last assessment titers ranged from
1:31.250 to 1:156.250. Thus, secondary immunomodula-
tion did not eliminate anti-rhGAA antibody titers. The
neutralizing effects of anti-rhGAA antibodies that were
observed in two patients before start of immunomodula-
tion disappeared. Before secondary immunomodulation,
all patients had experienced IARs; afterwards, none did
so. It is noteworthy that none experienced serious infec-
tious diseases during immunomodulation. We speculate
that IVIG administrations may have contributed to the
low infection rate.
It was difficult to fully judge the effect of immunomo-
dulation on clinical outcome parameters. The two
CRIM-negative patients who could walk at start main-
tained this ability. The patient who had lost this ability
did not regain it. We observed some positive impact on
the clinical stability.
Overview of the literature on secondary
immunomodulation: Effect on antibodies
To compare our results with those reported in the litera-
ture for the other patients with high titers receiving
immunomodulation [19, 20, 25–28], we have summarized
all reported data (8 patients) in Table 2. The first to pub-
lish their results were Messinger et al., who reported on
two CRIM-negative patients receiving secondary immuno-
modulation with RTX, MTX and IVIG [19]. These pa-
tients’ anti-rhGAA antibody titers were substantially lower
than those in our patients (maximum titer 1:12,800). The
patients remained antibody-free after B-cell recovery.
Subsequently Kazi et al. and Stenger et al. [20, 28]
reported on the addition of Bortezomib to the Messinger
protocol. They treated three patients with high
anti-rhGAA antibody titers (1:200,000–1:819,200). Titers
declined, or these patients were antibody-free at their
last assessment (0–1:1200) [20, 28], a fourth patient,
who received additional Cyclophosphamide instead of
Bortezomib, continued to have high titers (increase from
1:25,600 to 1:204,800; 1:102,400 at last assessment) [25].
Markic et el. and Deodato et al. used slightly different
protocols for two patients (one CRIM-negative and one
CRIM-positive) with low anti-rhGAA antibody titers
(1:6400 and 1:3200). After B-cell recovery titers
remained low to undetectable [26, 27].
In our study, anti-rhGAA antibody titers in one
CRIM-negative patient (patient 2) decreased substantially.
Previously, he had received primary immunomodulation
that had no effect on antibody titers [23]. When we de-
cided that the same patient should start secondary immu-
nomodulation at the age of 3.5 years, his titers were
1:800,000. An additional sample taken at the actual start
of secondary immunomodulation was slightly lower
(1:156,250) and declined further to 1:6250. It is unclear
whether the decline in titers was due entirely to immuno-
modulation, or whether a decline was already in progress.
At last assessment, the titer had increased to 1:31.250. In
our two other patients, we observed limited effects on
anti-rhGAA antibody titer. We conclude that the overall
effect of secondary immunomodulation in our study was
more limited than the effect of secondary immunomodu-
lation in the other reports.
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Fig. 3 Clinical outcome. All closed symbols represent measurements taken before secondary immunomodulation; all open symbols represent
measurements taken after immunomodulation, Circles: Patient 1, Squares: Patient 2, Triangels: Patient 3 a. AIMS score per patient during follow-
up. Grey areas represent normal values. b. BSID II age-equivalent score during follow-up. c. Distance walked during 6-min walk test in patients 1
and 2, patient 3 is too young to perform the 6MWT. Patient 1 lost the ability to walk at the age of 6.6 years (marked with asterisk). d. Time to run
10m in patients 1 and 2. Patient 1 lost the ability to perform this test at the age of 6.1 years (marked with asterisk). e. LVMI Z-score during follow-up.
f. FVC % of predicted relate to age in patient 1. Patients 2 and 3 are too young to perform a pulmonary function test
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Possible consequences of the different
immunomodulation protocols used
It must be noted that different secondary immunomodu-
lation protocols were used, and that it is not yet clear
how the differences between them may explain the
differences in anti-rhGAA antibody formation and elim-
ination. Seven of the eight patients reported in the litera-
ture received an initial round of weekly RTX infusions
[19, 20, 25, 27, 28]; thereafter, six of these patients con-
tinued to receive repeated RTX infusions every four to
12 weeks, to a maximum of 52 doses [19, 20, 27, 28].
RTX is a chimeric monoclonal antibody that induces
apoptosis of CD20-expressing B cells, but does not elim-
inate memory B cells. To eliminate memory B cells, Bor-
tezomib was added to the protocol, with Rapamycin to
modulate T-cell responses and IVIG to overcome the
period of immunoglobulin depletion. In addition, Rapa-
mycin may have an impact on glycogen storage by influ-
encing the mTOR pathway and inhibition of glycogen
synthase [35]. It is possible that longer and/or more
frequent dosing of RTX or Bortezomib could be more
effective in preventing immune responses.
We also conclude that there are differences in the
definition of and when to start immunomodulation. The
definition may also be influenced by slight differences
between the antibody assays used. In our earlier studies
we did not find inhibitory effects in patients with titers
below 1:31,250 [16]. Future research should seek to
identify the most successful secondary immunomodula-
tion protocol in patients with high sustained titers.
Overview of the literature on secondary
immunomodulation: Clinical outcome
As Table 2 shows, there are wide variations between the
clinical outcome reported for patients receiving second-
ary immunomodulation. While seven of the eight
patients reported in the literature (87.5%) were alive at
study end, only one (12.5%) remained ventilator-free and
learned to walk (patient 2 of Messinger et al.). This pa-
tient was the youngest at start of ERT (age 16 days), and
at study end was receiving 40 mg/kg/week of ERT.
In our patients, the overall clinical outcome was bet-
ter. Despite the development of high anti-rhGAA anti-
body titers, both of our CRIM-negative patients learned
to walk and had survived ventilator free even before the
start of secondary immunomodulation at the ages of 2.3
and 3.5 years. Banugaria et al. reported that it is very un-
likely that CRIM negative patients with high sustained
antibody titers survive ventilator free beyond the age of
2 years [21].
An important aspect of our study was that our
patients received a higher ERT dose of 40 mg/kg/week
from start of ERT. With a higher dosage, more
antibody-free rhGAA should be available, and the
neutralizing effects of the same titer are likely to be less
severe than in patients receiving 20mg/kg every other
week.
According to earlier estimates, as much as 54% of the
administered enzyme (about 10mg/kg) is antibody-bound
at a dose of 20mg/kg and a titer of 1:156,250 [16].
Theoretically, if a similar amount (10mg/kg) were bound
upon administration of 40mg/kg, about 30mg/kg would
still be available for uptake in the target tissues.
This may explain the overall better clinical outcome in
our CRIM-negative patients. After start of secondary
immunomodulation—which had been initiated due to a
decline in the quality of movements—one patient im-
proved on time tests, and the other, aged 3.8 years,
performed within the normal limits of the BSID II, even
though she had previously shown some deviation. The
CRIM-positive patient, who had lost the ability to walk,
stabilized.
In our study we were not able to eliminate antibodies.
We believe, however, that high rhGAA antibody titers
and, specifically the presence of neutralizing antibodies,
are relevant to a patient’s outcome. We also believe that
providing an adequate dose of rhGAA is just as
important.
Conclusion
While, to some extent, the immunomodulation protocol
used in our study reduced antibody titers, it did not
eliminate them. None of the patients experienced serious
infections and occurrence of IARs disappeared. Increases
in CK levels remained unexplained. Overall, there have
been few reports on secondary immunomodulation, and
various protocols have been applied. Future research
should seek to identify the most successful secondary
immunomodulation protocol in patients with high
sustained titers.
Additional file
Additional file 1: Figure S1. CK values measured over time for patient 1
(circle), patient 2 (square) and patient 3 (triangle). Closed symbols represent
CK values taken before secondary immunomodulation; all open symbols
represent measurements taken after immunomodulation. (TIF 778 kb)
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